Get the Stockscreener App
1.46
1.35%
-0.02
After Hours:
1.44
-0.02
-1.37%
Opko Health Inc stock is traded at $1.46, with a volume of 2.62M.
It is down -1.35% in the last 24 hours and down -2.01% over the past month.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Opko's diagnostics business includes a core genetic testing operation. It has a development and commercial supply pharmaceutical company, as well as a world supply-chain operation and holding company in Ireland. It also owns a specialty active pharmaceutical ingredients manufacturer in Israel. It operates in two segments Diagnostics and Pharmaceuticals.
See More
Previous Close:
$1.48
Open:
$1.47
24h Volume:
2.62M
Relative Volume:
0.84
Market Cap:
$996.46M
Revenue:
$863.49M
Net Income/Loss:
$-188.86M
P/E Ratio:
-5.4074
EPS:
-0.27
Net Cash Flow:
$-44.47M
1W Performance:
-8.75%
1M Performance:
-2.01%
6M Performance:
+12.31%
1Y Performance:
+8.15%
1-Day Range:
$1.42
$1.4799
1-Week Range:
$1.42
$1.61
52-Week Range:
$0.8516
$1.745
Opko Health Inc Stock (OPK) Company Profile
Name
Opko Health Inc
Sector
Industry
Phone
305-575-4181
Address
4400 BISCAYNE BLVD., MIAMI, FL
Opko Health Inc Stock (OPK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-29-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Jan-24-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-21-21 | Initiated | Ladenburg Thalmann | Buy |
| Nov-25-19 | Initiated | Piper Jaffray | Overweight |
| Mar-02-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-14-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-21-16 | Reiterated | Standpoint Research | Buy |
| Jun-03-16 | Initiated | Standpoint Research | Buy |
| Mar-31-16 | Reiterated | Barrington Research | Outperform |
| Oct-16-15 | Initiated | JP Morgan | Overweight |
| Sep-11-15 | Downgrade | Jefferies | Buy → Hold |
| Mar-03-15 | Downgrade | Oppenheimer | Outperform → Perform |
| May-12-14 | Reiterated | Oppenheimer | Outperform |
| Mar-14-14 | Initiated | Oppenheimer | Outperform |
| Nov-13-13 | Reiterated | Ladenburg Thalmann | Buy |
| May-30-13 | Reiterated | Ladenburg Thalmann | Buy |
| Oct-22-12 | Initiated | Barrington Research | Outperform |
| Dec-01-11 | Reiterated | Ladenburg Thalmann | Buy |
| Jul-14-11 | Initiated | Ladenburg Thalmann | Buy |
View All
Opko Health Inc Stock (OPK) Latest News
OPKO Health, Inc. (NASDAQ:OPK) Shares Bought by Assenagon Asset Management S.A. - MarketBeat
OPKO Health (OPK) Set to Announce Earnings on Thursday - MarketBeat
Head to Head Review: OPKO Health (NASDAQ:OPK) vs. OptiNose (NASDAQ:OPTN) - Defense World
OPKO Health, Inc.'s (NASDAQ:OPK) CEO Phillip Frost is the most upbeat insider, and their holdings increased by 9.6% last week - Simply Wall St
Here's Why You Should Retain OPKO Health Stock in Your Portfolio - MSN
OPKO Health to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times
Opko Health Inc (OPK-Q) QuotePress Release - The Globe and Mail
OPKO Health (NASDAQ:OPK) Trading 4.7% HigherShould You Buy? - MarketBeat
SECONDARY HYPERPARATHYROIDISM MARKET TO WITNESS UPSURGE - openPR
Us Prostate Cancer Instruments And Test Market Report: - openPR
With 50% ownership, OPKO Health, Inc. (NASDAQ:OPK) insiders have a lot riding on the company's future - Yahoo Finance
Hypopituitarism Market Forecasted to Surge in Coming Years, - openPR
35,157 Shares in OPKO Health, Inc. (NASDAQ:OPK) Bought by Algert Global LLC - Defense World
Renaissance Technologies LLC Cuts Stock Holdings in OPKO Health, Inc. (NASDAQ:OPK) - Defense World
OPK Gets Additional BARDA Funding to Develop Multispecific Antibodies - MSN
OPKO Health (NASDAQ:OPK) Stock Price Up 4.1%Time to Buy? - MarketBeat
Squarepoint Ops LLC Invests $592,000 in OPKO Health, Inc. (NASDAQ:OPK) - MarketBeat
Recent Analysts’ Ratings Updates for OPKO Health (OPK) - Defense World
Hsbc Holdings PLC Sells 28,560 Shares of OPKO Health, Inc. (NASDAQ:OPK) - Defense World
NextPlat expands OPKO e-commerce deal to Japan By Investing.com - Investing.com South Africa
ModeX secures additional $35 million for antibody research By Investing.com - Investing.com South Africa
Significant E-Commerce Expansions - Trend Hunter
ModeX secures additional $35 million for antibody research - Investing.com
NextPlat expands OPKO e-commerce deal to Japan - Investing.com India
OPKO Health's (OPK) ModeX Therapeutics Secures $35M BARDA Supplement - StreetInsider.com
ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program - StockTitan
OPKO Health (NASDAQ:OPK) Trading Up 5% - MarketBeat
Labcorp’s $237.5 Million Acquisition of Assets of OPKO Health - Global Legal Chronicle
Opko Health Inc’s: Contrasting Stock Performances in a Volatile Market - The InvestChronicle
OPK’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
Upward Trajectory: Opko Health Inc (OPK) Posts a Gaine, Closing at 1.52 - The Dwinnex
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data - MSN
Opko Health stock maintains Buy rating from H.C. Wainwright on positive data - Investing.com Canada
OPKO Health's (OPK) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
OPKO Health (NASDAQ:OPK) Receives "Buy" Rating from HC Wainwright - MarketBeat
Entera Bio and OPKO Health report promising obesity treatment study By Investing.com - Investing.com Australia
Entera Bio and OPKO Health report promising obesity treatment study - Investing.com
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide - EIN News
OPKO Health (NASDAQ:OPK) Trading Down 2% - MarketBeat
ModeX Therapeutics appoints new Chief Medical Officer By Investing.com - Investing.com Canada
OPKO Health (NASDAQ:OPK) Shares Gap Down to $1.48 - MarketBeat
OPKO Health’s ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development - XM
ModeX Therapeutics appoints new Chief Medical Officer - Investing.com
OPKO Health's (OPK) ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development - StreetInsider.com
OPKO Health, Inc. (NASDAQ:OPK) Stake Boosted by Rubric Capital Management LP - MarketBeat
OPKO Health (NASDAQ:OPK) Rating Reiterated by Barrington Research - MarketBeat
Labcorp Stock Gains From Its Latest Acquisition of BioReference Health - MSN
HC Wainwright Reiterates “Buy” Rating for OPKO Health (NASDAQ:OPK) - Defense World
OPKO Health (NASDAQ:OPK) Stock Price Down 2.4% - MarketBeat
OPKO Health (NASDAQ:OPK) Given Overweight Rating at Piper Sandler - Defense World
Opko Health Inc Stock (OPK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Opko Health Inc Stock (OPK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| OPKO HEALTH, INC. | 10% Owner |
Aug 19 '24 |
Sale |
34.49 |
50,000 |
1,724,520 |
2,646,972 |
| OPKO HEALTH, INC. | 10% Owner |
Aug 16 '24 |
Sale |
34.30 |
50,000 |
1,714,850 |
2,696,972 |
| OPKO HEALTH, INC. | 10% Owner |
Aug 15 '24 |
Sale |
33.08 |
39,824 |
1,317,505 |
2,746,972 |
| OPKO HEALTH, INC. | 10% Owner |
Aug 12 '24 |
Sale |
33.95 |
59,787 |
2,029,811 |
2,811,783 |
| OPKO HEALTH, INC. | 10% Owner |
Aug 13 '24 |
Sale |
34.76 |
24,987 |
868,503 |
2,786,796 |
| OPKO HEALTH, INC. | 10% Owner |
Aug 08 '24 |
Sale |
31.82 |
100,000 |
3,182,380 |
2,871,570 |
| OPKO HEALTH, INC. | 10% Owner |
Aug 06 '24 |
Sale |
29.35 |
12,994 |
381,427 |
2,971,570 |
| OPKO HEALTH, INC. | 10% Owner |
Jul 31 '24 |
Sale |
33.50 |
88,839 |
2,976,346 |
2,984,564 |
| OPKO HEALTH, INC. | 10% Owner |
Jul 29 '24 |
Sale |
33.86 |
50,000 |
1,692,890 |
3,073,403 |
| OPKO HEALTH, INC. | 10% Owner |
Jul 24 '24 |
Sale |
33.72 |
75,000 |
2,529,105 |
3,183,403 |
3.48%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):